Research Analysts’ Price Target Changes for December 29th (ACN, AUTL, COIN, ENPH, ETOR, EXPE, GEMI, HAS, HOOD, KBH)

Research Analysts’ price target changes for Monday, December 29th:

Accenture (NYSE:ACN) had its price target trimmed by Argus from $370.00 to $335.00. Argus currently has a buy rating on the stock.

Autolus Therapeutics (NASDAQ:AUTL) had its target price boosted by Needham & Company LLC from $10.00 to $11.00. The firm currently has a buy rating on the stock.

Coinbase Global (NASDAQ:COIN) had its target price lowered by Needham & Company LLC from $400.00 to $290.00. They currently have a buy rating on the stock.

Enphase Energy (NASDAQ:ENPH) had its price target raised by Northland Securities from $52.00 to $62.00. The firm currently has an outperform rating on the stock.

eToro Group (NASDAQ:ETOR) had its target price trimmed by Needham & Company LLC from $68.00 to $58.00. They currently have a buy rating on the stock.

Expedia Group (NASDAQ:EXPE) had its price target boosted by Argus from $300.00 to $340.00. They currently have a buy rating on the stock.

Gemini Space Station (NASDAQ:GEMI) had its price target lowered by Needham & Company LLC from $35.00 to $23.00. Needham & Company LLC currently has a buy rating on the stock.

Hasbro (NASDAQ:HAS) had its price target raised by Jefferies Financial Group Inc. from $90.00 to $95.00. They currently have a buy rating on the stock.

Robinhood Markets (NASDAQ:HOOD) had its price target lowered by Needham & Company LLC from $145.00 to $135.00. They currently have a buy rating on the stock.

KB Home (NYSE:KBH) had its price target reduced by JPMorgan Chase & Co. from $71.00 to $50.00. The firm currently has a neutral rating on the stock.

Mereo BioPharma Group (NASDAQ:MREO) had its target price cut by BTIG Research from $6.00 to $1.00. BTIG Research currently has a buy rating on the stock.

Synaptics (NASDAQ:SYNA) had its target price raised by Northland Securities from $85.00 to $106.00. They currently have an outperform rating on the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target boosted by Leerink Partners from $456.00 to $525.00. They currently have an outperform rating on the stock.